


<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>PHOE-0061</b>	Serial No. <b>09/921,380</b>
		Applicant <b>Charles Mark Ensor, et al.</b>	
		Filing Date <b>August 2, 2001</b>	Group <u>1652</u> <b>Not Yet Assigned</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<u>CP</u>	<b>AA</b>	Chen R. et al., "Properties of two urate oxidases modified by the covalent attachment of poly(Ethylene Glycol), Biochim. Biophys. Acta 660, 1981, pp 293-298	
<u>CP</u>	<b>AB</b>	Chua C.C. et al., "Use of polyethylene glycol-modified uricase (Peg-Uricase) to treat hyperuricemia in a patient with non-hodgkin lymphoma", <i>Ann Intern. Med.</i> 1988, 109, pp 114-117	
<u>CP</u>	<b>AC</b>	Davis, S. et al., "Hypouricaemic effect of polyethyleneglycol modified urate oxidase" <i>The Lancet</i> 2, 1981, pp 281-283 ✓	
<u>CP</u>	<b>AD</b>	Delgado C. et al., "The uses and properties of PEG-linked proteins", <i>Crit. Rev. Ther. Drug Carrier Sys.</i> , 1992, 9, pp 249-304	
<u>CP</u>	<b>AE</b>	G. Masera et al., <i>Ann. Oncol</i> 8, 1996, 407 (attention)	
<u>CP</u>	<b>AF</b>	Hande, K.R. et al., "Acute tumor lysis syndrome in patients with high-grade non-hodgkin's lymphoma", <i>Am J. Med.</i> 1993, 94, pp 133-139	
<u>CP</u>	<b>AG</b>	Jankovic M et al., "Urate-oxidase as hypouricemic agent in a case of acute tumor lysis syndrome", <i>Am J Pediatr. Hematol. Oncol.</i> , 1985, 7, pp 202-204	
<u>CP</u>	<b>AH</b>	Jones D.P. et al., "Tumor lysis syndrome: pathogenesis and management, <i>Pediatr Nephrol</i> , 1995, 9, pp 206-212	
<u>CP</u>	<b>AI</b>	Kalmkerian, G.P. et al., "Tumor lysis syndrome in small cell carcinoma and other solid tumors", <i>Am J. Med.</i> 1997, 103, pp 363-367	
<u>CP</u>	<b>AJ</b>	Kelley, W.N. et al., "Crystal-associated synovitis, Gout and hyperuricemia, <i>R.L. Textbook of Rheumatology</i> , 5 <sup>th</sup> edition, 1997, pp 1313-1351	
<b>EXAMINER</b> <u>CP</u>		<b>DATE CONSIDERED</b> <u>11/14/02</u>	

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
**PHOE-0061**

Serial No.  
**09/921,380**

Applicant  
**Charles Mark Ensor et al.**

Filing Date  
**August 2, 2001**

Group **1652**  
**Not Yet Assigned**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<b>AK</b>	Lauter, CB et al., "Microbiologic assays and neurological toxicity during use of adenine arabinoside in humans", <i>Am J. Infect Dis</i> , 1976, 134, pp 75-79
<b>AL</b>	London M. et al., "Uricolytic activity of purified uricase in two human beings", <i>Science</i> 1957, 125, pp 937-938
<b>AM</b>	Lorigan, P.C. et al., "tumour lysis syndrome, case report and review of the literature" <i>Ann Oncol</i> , 1996, 7, pp 631-636
<b>AN</b>	Masera G. et al., "Urate-oxidase prophylaxis of uric acid-induced renal damage in childhood leukemia, <i>J Pediatrics</i> , 1982, 100, pp 152-155
<b>AO</b>	Monfardini, C et al., "A branched monomethoxypoly (ethylene glycol) for protein modification", <i>Bioconjugate Chem</i> , 1995, 6, pp 62-69
<b>AP</b>	Nishimara, H. et al., "Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzyme activity, <i>Enzyme</i> , 1981, 26, pp 49-53
<b>AQ</b>	Oberling, F. et al., J.M. Nouvelle Presse Med 3, <del>1993</del> <sup>1974</sup> 2026
<b>AR</b>	Parek et al., "Pharmacology of escherichia coli-l-asparaginase polyethylene glycol adduct", <i>Anticancer Res.</i> , 1981, 1, pp 373-376
<b>AS</b>	Pui C. et al., "Urate oxidase in prevention and treatment of hyperuricemia associated with lymphoid malignancies", <i>Leukemia</i> , 1997, pp 1813-1816
<b>EXAMINER</b>	<b>DATE CONSIDERED</b> <b>11/14/02</b>

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
**PHOE-0061**

Serial No.  
**09/921,380**

Applicant  
**Charles Mark Ensor et al.**

Filing Date  
**August 2, 2001**


Group **1652**  
**Not Yet Assigned**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<i>CM</i>	<b>AT</b>	Savoca, K. et al., "Induction of tolerance in mice by uricase and monomethoxypolyethylene glycol-modified uricase", <i>Int Archs. Allergy Appl. Immun.</i> <b>1984</b> , 75, pp 58-67
<i>CM</i>	<b>AU</b>	Tsuji, J. et al., "Studies on antigenicity of the polyethylene glycol(PEG)-modified uricase", <i>Int J Immunopharmac</i> , <b>1985</b> , 7, pp 725-730
<i>CM</i>	<b>AV</b>	Woloshuk et al., "Genetic transformation system for the aflatoxin-producing fungus aspergillus flavus", <i>Applied Environ. Microbiol</i> , <b>1989</b> , 55, pp 86-90
<i>CM</i>	<b>AW</b>	Wu, et al., "Hyperuricemia and urate nephropathy in urate oxidase-deficient mice", <i>Proc Natl Acad Sci USA</i> , <b>1994</b> , 91, pp 742-6
<i>CM</i>	<b>AX</b>	Wu, et al., "Two independent mutational events in the loss of urate oxidase during hominoid evolution", <i>J. Mol Evol.</i> <b>1992</b> , 34, pp 78-84
<i>CM</i>	<b>AY</b>	Zalipsky, S et al., Polyethylene Glycol Chemistry: Biotechnical and biomedical applications, <i>Topics in Applied Chemistry</i> , Plenum Press, New York, <b>1992</b> , pp 347-370
*	<b>AZ</b>	<del>Zaplipsky et al., Polyethylene Glycol chemistry: Biotechnical and Biomedical Applications, J.M. Harris ed., Plenum Press, NY, Chapter 21 (1992)</del>

**EXAMINER** *CM Allen***DATE CONSIDERED** *11/14/02*

\*A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
**PHOE-0061**

Serial No.  
**09/921,380**

Applicant  
**Charles Mark Ensor, et al.**

Filing Date  
**August 2, 2001**

Group **1052**  
**Not Yet Assigned**

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
<i>BA</i>	<b>BA</b>	4,062,731	12/13/77	Snoke et al.	195	62
<i>BB</i>	<b>BB</b>	4,064,010	12/20/77	Harris et al.	195	62
<i>BC</i>	<b>BC</b>	4,273,874	06/16/81	Nakanishi et al.	435	191
<i>BD</i>	<b>BD</b>	4,317,878	03/02/82	Nakanishi et al.	435	10
<i>BE</i>	<b>BE</b>	4,389,485	06/21/83	Olivieri et al.	435	191
<i>BF</i>	<b>BF</b>	4,394,450	07/19/83	Brock et al.	435	191
<i>BG</i>	<b>BG</b>	4,460,683	07/17/84	Gloger et al.	435	10
<i>BH</i>	<b>BH</b>	4,882,280	11/21/89	Takashio et al.	435	228
<i>BI</i>	<b>BI</b>	4,987,076	01/22/91	Takashio et al.	435	191
<i>BJ</i>	<b>BJ</b>	5,376,545	12/27/94	Yagasaki et al.	435	191
<i>BK</i>	<b>BK</b>	5,700,674	12/23/97	Koyama et al.	435	191
<i>BL</i>	<b>BL</b>	5,728,652	03/17/98	Shigyo et al.	435	191
<i>BM</i>	<b>BM</b>	5,801,036	09/01/98	Koyama et al.	435	191

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
<b>EXAMINER</b> <i>CHAKKON</i>				<b>DATE CONSIDERED</b> <i>7/14/02</i>		